Effect Of Complete Decongestive Therapy On Carpal Tunnel Syndrome Post Upper Limb Lymphedema (CDT)

Cairo University (CU)

Status: Not yet enrolling

Conditions: Lymphedema

Treatments: Other: Medical treatment; Other: Complete decongestive therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT05932381

P.T.REC/012/003738

Details and patient eligibility

About

this study will be conducted to investigate the therapeutic effect of complete decongestive therapy on carpal tunnel syndrome post-upper limb lymphedema.

Full description

lymphedema is a chronic condition characterized by lymphatic vessel ectasia and valve dysfunction, followed by the reflux of lymphatic fluid into the interstitial space. Lymph stasis may lead to a chronic inflammatory process, resulting in adipose tissue differentiation and fibro adipose tissue deposition. One consequence of post-mastectomy lymphedema may be the development of nerve entrapments. One example is median nerve entrapment in the carpal canal, or carpal tunnel syndrome (CTS). many studies assessed the relationship of CTS as a risk factor for developing lymphedema, other studies stated the possibility of lymphedema as a potential contributor to CTS development. Complex decongestive treatment of breast cancer-related lymphoedema is an accepted strategy and is considered as an international standard for treatment. A previous review concluded that complex decongestive therapy has a positive impact on the volume of arm and quality of life in different stages of lymphedema.sixty females will be allocated randomly to two groups; first one will receive decongestive therapy and the second one will receive the routine medical treatment for ten weeks

Enrollment: 60 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age will range between 20- 40 years.
• Only females will participate in the study.
• All patients have carpal tunnel syndrome post upper limb lymphedema.

Exclusion criteria

• Diabetes mellitus.
• Individuals with cardiopulmonary conditions.
• Individuals undergoing radiation therapy or chemotherapy.
• Hepatic or pancreatic diseases.
• Sensory impairment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Complete decongestive therapy

Experimental group

Description:

the patients will receive complete decongestive therapy twice a week for ten weeks

Treatment:

Other: Medical treatment

Other: Complete decongestive therapy

medical treatment

Active Comparator group

Description:

the patients will receive routine medical treatment for ten weeks

Treatment:

Other: Medical treatment